Genetic Chronic Obstructive Pulmonary Disease (COPD) Market, By Drug Class (Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Steroids, Antibiotics and Others), By Route of Administration (Oral and Nasal), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) -

Published In : Jan 2023

Code : CMI5512

Pages :178

Formats :

Excel and PDF

Industry : Pharmaceutical

Genetic Chronic Obstructive Pulmonary Disease (COPD) MarketSize and Trends

Global genetic chronic obstructive pulmonary disease (COPD) market is estimated to be valued at US$ 560.3 million in 2022 and is expected to exhibit a CAGR of 3.2% during the forecast period (2022-2030).

Figure 1. Global Genetic Chronic Obstructive Pulmonary Disease (COPD) Market Share (%), by Distribution Channel, 2022

Genetic Chronic Obstructive Pulmonary Disease (COPD) Market: Drivers

Increasing prevalence of chronic obstructive pulmonary disease (COPD), associated with awareness efforts carried out by individual organizations is expected to drive the global genetic chronic obstructive pulmonary disease (COPD) market growth over the forecast period.

Increasing prevalence of chronic obstructive pulmonary disease is expected to drive the global genetic chronic obstructive pulmonary disease (COPD) market growth over the forecast period. For instance, according to fact sheet published by World Health Organization in May 2022, Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide, causing 3.23 million deaths in 2019. Moreover, in November 2021, according to the data published by the National Heart, Lung and Blood Institute, each November, the chronic obstructive pulmonary disease (COPD) community comes together to promote better understanding of chronic obstructive pulmonary disease (COPD), a progressive lung disease that affects a lot of people across the U.S. Increasing awareness about chronic obstructive pulmonary disease (COPD) and its symptoms is important because early diagnosis and treatment can improve quality of life.

Figure 2.Global genetic chronic obstructive pulmonary disease (COPD) Market Share (%), by Region, 2022